These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 22031823)
1. Identification of allele-specific RNAi effectors targeting genetic forms of Parkinson's disease. Sibley CR; Wood MJ PLoS One; 2011; 6(10):e26194. PubMed ID: 22031823 [TBL] [Abstract][Full Text] [Related]
2. Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi. de Yñigo-Mojado L; Martín-Ruíz I; Sutherland JD PLoS One; 2011; 6(6):e21352. PubMed ID: 21712955 [TBL] [Abstract][Full Text] [Related]
3. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease. Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063 [TBL] [Abstract][Full Text] [Related]
4. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease. Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749 [TBL] [Abstract][Full Text] [Related]
5. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil. Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137 [TBL] [Abstract][Full Text] [Related]
6. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases. Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310 [TBL] [Abstract][Full Text] [Related]
8. α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of Parkinson disease. Covy JP; Giasson BI Neurotoxicology; 2011 Oct; 32(5):622-9. PubMed ID: 21238487 [TBL] [Abstract][Full Text] [Related]
9. The SNCA (A53T, A30P, E46K) and LRRK2 (G2019S) mutations are rare cause of Parkinson's disease in South Indian patients. Vishwanathan Padmaja M; Jayaraman M; Srinivasan AV; Srikumari Srisailapathy CR; Ramesh A Parkinsonism Relat Disord; 2012 Jul; 18(6):801-2. PubMed ID: 22436655 [No Abstract] [Full Text] [Related]
10. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease. Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865 [TBL] [Abstract][Full Text] [Related]
11. Autosomal dominant Parkinson's disease and the route to new therapies. Morris HR Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248 [TBL] [Abstract][Full Text] [Related]
12. Age at onset in LRRK2-associated PD is modified by SNCA variants. Botta-Orfila T; Ezquerra M; Pastor P; Fernández-Santiago R; Pont-Sunyer C; Compta Y; Lorenzo-Betancor O; Samaranch L; Martí MJ; Valldeoriola F; Calopa M; Fernández M; Aguilar M; de Fabregas O; Hernández-Vara J; Tolosa E J Mol Neurosci; 2012 Sep; 48(1):245-7. PubMed ID: 22669510 [TBL] [Abstract][Full Text] [Related]